Stockscreener 앱 받기
1.7146
0.87%
-0.0154
전일 마감가:
$1.73
열려 있는:
$1.72
하루 거래량:
262.89K
Relative Volume:
0.12
시가총액:
$93.56M
수익:
-
순이익/손실:
$-59.69M
주가수익비율:
-1.2335
EPS:
-1.39
순현금흐름:
$-46.54M
1주 성능:
-0.29%
1개월 성능:
+40.57%
6개월 성능:
+0.88%
1년 성능:
+23.38%
1일 변동 폭
$1.67
$1.79
1주일 범위
$1.62
$1.80
52주 변동 폭
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
MIST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.715 | 93.56M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.86 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.34 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.10 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
253.92 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Milestone Pharmaceuticals (MIST) Awaits FDA Decision on Cardamyst Resubmission - GuruFocus
Milestone Pharmaceuticals Files Response to FDA for Cardamyst Nasal Spray - marketscreener.com
Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha
Milestone Pharmaceuticals Submits Response to FDA for CARDAMYST - TipRanks
Milestone Pharmaceuticals submits response to FDA for PSVT drug - Investing.com
Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting - The Manila Times
Milestone Pharmaceuticals Submits Response To The FDA's CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting - marketscreener.com
Milestone's CARDAMYST Could Become First Self-Administered PSVT Treatment After FDA Response - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to “Buy” at HC Wainwright - Defense World
Milestone Pharmaceuticals (MIST) Receives Buy Rating from HC Wai - GuruFocus
Milestone Pharmaceuticals (MIST) Receives Buy Rating with $5 Tar - GuruFocus
Milestone Pharmaceuticals (MIST) Receives Buy Rating from HC Wainwright | MIST Stock News - GuruFocus
Northern Trust Corp Purchases 30,772 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals completes US$94.9M initial public offering - McCarthy Tétrault
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Millennium Management LLC - Defense World
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - The Manila Times
Milestone Pharmaceuticals Executives Set for Key Presentation at Jefferies Healthcare Conference - Stock Titan
Analysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Target Price at $17.00 - Defense World
Milestone Payments: Potential Trouble In The Last Mile? - Life Science Leader
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why - Yahoo Finance
Cubist Systematic Strategies LLC Takes $73,000 Position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Milestone Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Milestone Pharmaceuticals Reports First Quarter 2025 Financial R - GuruFocus
Milestone Pharmaceuticals Navigates Regulatory Challenges and Financial Updates in Q1 2025 - TipRanks
Milestone Pharmaceuticals (MIST) Aims to Resolve FDA Issues for CARDAMYST | MIST Stock News - GuruFocus
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results - marketscreener.com
Milestone Pharmaceuticals reports Q1 EPS (31c) vs (21c) last year - TipRanks
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone's CARDAMYST Gets FDA Path Forward: Manufacturing Issues Only, $56M Cash Runway Revealed - Stock Titan
Milestone Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - GlobeNewswire
Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Monday - Defense World
Milestone Pharmaceuticals Inc (MIST) Stock: A Closer Look at the Analyst Ratings - News Heater
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial - GlobeNewswire
MIST’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
What is Milestone Pharmaceuticals Inc (MIST) Stock Return on Shareholders’ Capital? - Sete News
Deeper Dive: Understanding Milestone Pharmaceuticals Inc (MIST) Through its Various Ratios - DWinneX
Stock Market Recap: Milestone Pharmaceuticals Inc (MIST) Concludes at 0.88, a -60.89 Surge/Decline - DWinneX
The Attractiveness of Investing In Milestone Pharmaceuticals Inc (MIST) is Growing - knoxdaily.com
Milestone Pharmaceuticals Inc (MIST)’s stock price range in the last year - uspostnews.com
Milestone Pharmaceuticals Inc (MIST) looking to reclaim success with recent performance - Sete News
Market Watch Highlights: Milestone Pharmaceuticals Inc (MIST) Ends on an Upturn Note at 1.06 - DWinneX
Milestone Pharmaceuticals Inc’s Mixed Bag: Down -30.82% in 6 Months, Down -48.21% in 30 Days - investchronicle.com
A stock that deserves closer examination: Milestone Pharmaceuticals Inc (MIST) - uspostnews.com
Milestone Pharmaceuticals Inc [MIST] Investment Guide: What You Need to Know - knoxdaily.com
Examining Milestone Pharmaceuticals Inc (MIST) stock is warranted - uspostnews.com
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT - Seeking Alpha
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.59%
0.56%
자본화:
|
볼륨(24시간):